Real-world use of lacosamide in epilepsy: results from a cross-sectional survey of neurologists in India
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20252947Keywords:
Epilepsy, Lacosamide, Survey, NeurologistsAbstract
Background: Epilepsy affects over 50 million people worldwide, having significant burden in countries like India. Despite existing antiepileptic drugs (AEDs), many patients face suboptimal seizure control or side effects. This survey aimed to assess how Indian neurologists use lacosamide in routine epilepsy care.
Methods: A cross-sectional, questionnaire-based survey was conducted across India between January and March 2025, involving 244 neurologists actively managing epilepsy cases. The 20-item survey questionnaire covered clinical scenarios for lacosamide use, dosing and titration strategies, efficacy perceptions, safety practices, drug-drug interactions, application in special populations, intravenous use, and patient adherence. Responses were collected anonymously and analyzed descriptively.
Results: This survey of Indian neurologists reveals widespread use of lacosamide, primarily for focal-onset seizures in both refractory (55.3%) and newly diagnosed (49.6%) cases. It is mostly used as adjunctive therapy (70.5%), with some using it as monotherapy according to patient needs. Safety and tolerability (63.1%) are the primary drivers for prescribing lacosamide, with efficacy (42.6%) as a key secondary factor. Seizure control is often achieved within 2–4 weeks (49.2%) and its use in pediatric and elderly patients is selective, with lower starting doses. Overall, 92.6% of neurologists reported satisfaction with lacosamide in clinical practices.
Conclusions: The findings highlight lacosamide as a well-accepted and widely utilized antiepileptic drug among Indian neurologists, valued for its safety, tolerability, and efficacy. Its flexible use across diverse patients, especially in focal-onset seizures, combined with high clinician satisfaction, reinforces its role as a trusting option in real-world epilepsy management.
Metrics
References
World Health Organization. Epilepsy. 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/epilepsy. Accessed on 02 May 2025.
American Association of Neurological Surgeons. Epilepsy. 2024. Available at: https://www.aans. org/patients/conditions-treatments/epilepsy/. Accessed on 02 May 2025.
Singh G, Sander JW. The global burden of epilepsy report: Implications for low- and middle-income countries. Epilepsy Behav. 2020;105:106949. DOI: https://doi.org/10.1016/j.yebeh.2020.106949
Mehndiratta MM, Aggarwal V. Neurological disorders in India: past, present, and next steps. Lancet Glob Health. 2021;9(8):e1043-4. DOI: https://doi.org/10.1016/S2214-109X(21)00214-X
Perucca E, Yasothan U, Clincke G, Kirkpatrick P. Lacosamide. Nat Rev Drug Discov. 2008;7(12):973-4. DOI: https://doi.org/10.1038/nrd2764
Zhuo C, Jiang R, Li G, Shao M, Chen C, Chen G, et al. Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis. Sci Rep. 2017;7(1):2535. DOI: https://doi.org/10.1038/s41598-017-02525-2
Espinosa-Jovel C, Valencia N, Gaitán L, Riveros S. Impact of Third-Generation Antiseizure Medications on People with Epilepsy in a Low-Income Population: The Brivaracetam Experience in a Real-World Study. Drugs Real World Outcomes. 2024;11(3):477-85. DOI: https://doi.org/10.1007/s40801-024-00445-y
Carona A, Bicker J, Silva R, Fonseca C, Falcão A, Fortuna A. Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. Life Sci. 2021;275:119342.
CDSCO. Lacosamide. Available at: https:// cdscoonline.gov.in/CDSCO/Drugs. Accessed on 02 May 2025.
Wilson SM, Khanna R. Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide. Mol Neurobiol. 2015;51(2):599-609. DOI: https://doi.org/10.1007/s12035-014-8775-9
Krauss GL, Edwards HB, Lin B. Lacosamide for the treatment of epilepsy. Ann Med. 2012;44(7):674-9. DOI: https://doi.org/10.3109/07853890.2011.603700
Carona A, Bicker J, Silva R, Fonseca C, Falcão A, Fortuna A. Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. Life Sci. 2021;275:119342. DOI: https://doi.org/10.1016/j.lfs.2021.119342
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551-63. DOI: https://doi.org/10.1111/epi.12074
Perucca E. The pharmacological treatment of epilepsy: recent advances and future perspectives. Acta Epileptologica. 2021;3(1). DOI: https://doi.org/10.1186/s42494-021-00055-z
Zhao T, Yu LH, Zhang HL, Yu J, Feng J, Wang TT, et al. Long-term effectiveness and safety of lacosamide as adjunctive therapy in children and adolescents with refractory epilepsy: a real-world study. BMC Pediatr. 2023;23(1):249. DOI: https://doi.org/10.1186/s12887-023-04039-5
Jin Y, Zhang R, Jiang J, Liu X. Efficacy and tolerability of lacosamide as adjunctive therapy in patients with focal-onset seizures: an observational, prospective study. Acta Neurol Belg. 2023;123(3):1081-7.
Villanueva V, Giráldez BG, Toledo M, De Haan GJ, Cumbo E, Gambardella A, et al. Lacosamide monotherapy in clinical practice: A retrospective chart review. Acta Neurol Scand. 2018;138(3):186-94. DOI: https://doi.org/10.1111/ane.12920
Babar RK, Bresnahan R, Gillespie CS, Michael BD. Lacosamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev. 2021;5(5):CD008841. DOI: https://doi.org/10.1002/14651858.CD008841.pub3
Hou L, Peng B, Zhang D, Yang J, Wang Y, Tong L, et al. Clinical Efficacy and Safety of Lacosamide as an Adjunctive Treatment in Adults With Refractory Epilepsy. Front Neurol. 2021;12:712717. DOI: https://doi.org/10.3389/fneur.2021.712717
Yang C, Peng Y, Zhang L, Zhao L. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12:694381.
Vossler DG, Knake S, O'Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, Williams P, et al. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2020;91(10):1067-75. DOI: https://doi.org/10.1136/jnnp-2020-323524
Ortiz de la Rosa JS, Ladino LD, Rodríguez PJ, Rueda MC, Polanía JP, Castañeda AC. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. Seizure. 2018;56:34-40. DOI: https://doi.org/10.1016/j.seizure.2018.01.014
Zuberi SM, JD Symonds, Update on diagnosis and management of childhood epilepsies. J Pediatr (Rio J). 2015;91(6 Suppl 1):S67-77. DOI: https://doi.org/10.1016/j.jped.2015.07.003
Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet. 2000;355(9213):1441-6. DOI: https://doi.org/10.1016/S0140-6736(00)02149-8
Jin Y, Zhang R, Jiang J, Liu X. Efficacy and tolerability of lacosamide as adjunctive therapy in patients with focal-onset seizures: an observational, prospective study. Acta Neurol Belg. 2023;123(3):1081-7. DOI: https://doi.org/10.1007/s13760-023-02236-8
Liu W, Li W, Wang P, Zhang H, Zhang E, Wu X, et al. Lacosamide as the first add-on therapy in adult patients with focal epilepsy: A multicenter real-world study. Front Neurol. 2023;14:1136814. DOI: https://doi.org/10.3389/fneur.2023.1136814
Yang C, Peng Y, Zhang L, Zhao L. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12:694381. DOI: https://doi.org/10.3389/fphar.2021.694381
Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958-67. DOI: https://doi.org/10.1111/j.1528-1167.2009.02496.x
Downloads
Published
How to Cite
Issue
Section
